Related Experiment Video

Updated: Feb 11, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

ASB1 differential methylation in ischaemic cardiomyopathy: relationship with left ventricular performance in

Ana Ortega1, Estefanía Tarazón1, Carolina Gil-Cayuela1

  • 1Cardiocirculatory Unit, Health Research Institute of La Fe University Hospital (IIS La Fe), Avd. Fernando Abril Martorell, 106, 46026, Valencia, Spain.

ESC Heart Failure
|April 19, 2018
PubMed

Insights

Epigenetic analysis reveals a specific ASB1 gene methylation pattern in ischaemic cardiomyopathy (ICM) patients. This epigenetic alteration correlates with impaired left ventricular function and structure, suggesting new therapeutic targets for heart failure.

Area of Science:

  • Cardiovascular Epigenetics
  • Molecular Cardiology
  • Gene Expression Regulation

Background:

  • Ischaemic cardiomyopathy (ICM) significantly impairs cardiac function, leading to high mortality.
  • Epigenetic modifications, such as DNA methylation, play a crucial role in disease pathogenesis.
  • Understanding epigenetic signatures in ICM can reveal novel therapeutic targets.

Purpose of the Study:

  • To investigate differential epigenetic patterns of the ASB gene family in ICM patients.
  • To correlate these epigenetic alterations with the haemodynamic and functional status of the left ventricle (LV).
  • To identify potential epigenetic biomarkers for ICM progression and severity.

Main Methods:

  • Epigenomic analysis of left ventricular (LV) tissue samples from ICM patients and control subjects.
  • RNA sequencing to assess ASB1 gene expression levels.
  • Pyrosequencing to validate differential methylation patterns of ASB1.

Main Results:

  • A hypermethylated profile (cg11189868) was identified in the ASB1 gene in ICM patients.
  • ASB1 hypermethylation significantly correlated with reduced LV ejection fraction and stroke volume.
  • ASB1 messenger RNA levels were down-regulated in ICM, suggesting a link between methylation and gene expression.

Conclusions:

  • A specific ASB1 methylation pattern is associated with impaired LV structure and function in end-stage ICM.
  • These findings highlight the role of ASB1 epigenetics in the pathophysiology of heart failure.
  • The study opens avenues for novel therapeutic strategies targeting ASB1 in ICM.
Abstract

Keywords:
ASB1EpigenomicsHeart failureIschaemic cardiomyopathyLeft ventricular dysfunctionStroke volume

More Related Videos

Patient-specific Modeling of the Heart: Estimation of Ventricular Fiber Orientations12:09

Patient-specific Modeling of the Heart: Estimation of Ventricular Fiber Orientations

Published on: January 8, 2013

14.1K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.7K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
360